Police Search for Missing Alzheimer’s Patient in Toms River
TOMS RIVER, NJ — The Toms River Police Department is
Alzheimer’s
Biogen to discontinue development of older Alzheimer’s drug Aduhelm
(Reuters) – Biogen Inc said on Wednesday it would terminate
Researchers return to Alzheimer’s vaccines, buoyed by recent drug success
By Julie Steenhuysen CHICAGO (Reuters) – Breakthrough Alzheimer’s treatments that
Blood tests needed for widespread Alzheimer’s diagnosis on the way
By Deena Beasley (Reuters) – Blood tests for Alzheimer’s are
Down syndrome families’ fight for access to Alzheimer’s trials, treatments
By Julie Steenhuysen CHICAGO (Reuters) – When Lianor da Cunha
Newark Police Seek Assistance in Locating Missing 70-Year-Old Man with Alzheimer’s
NEWARK, NJ – Newark Public Safety Director Fritz G. Fragé
Major US health systems expect to offer Alzheimer’s drug Leqembi in a few months
By Julie Steenhuysen and Deena Beasley CHICAGO (Reuters) – Five
Factbox-Companies in Alzheimer’s race after US nod for Eisai/Biogen drug
(Reuters) – Eisai Co Ltd and Biogen Inc’s Leqembi emerged
Explainer-Who is eligible for the new FDA-approved Alzheimer’s drug?
By Deena Beasley The U.S. Food and Drug Administration on
Medicare offers details on reimbursement for new Alzheimer’s drugs
By Julie Steenhuysen CHICAGO (Reuters) -The U.S. Medicare health plan
After weight loss, Alzheimer’s may be next frontier for drugs like Ozempic
By Natalie Grover LONDON (Reuters) – Diabetes drugs that also
Exclusive-Lilly expects US Medicare to reverse course, fully cover Alzheimer’s drugs
By Deena Beasley and Julie Steenhuysen (Reuters) – Eli Lilly
JAMES CARTER AND JAMES PINKERTON: There’s A Major Obstacle To Finding The Cure For Alzheimer’s
JAMES CARTER AND JAMES PINKERTON: There’s A Major Obstacle To
Eisai, Biogen’s Alzheimer’s drug price should not dent demand – analysts
(Reuters) – The $26,500-per-year price tag for Eisai Co Ltd
Eisai files for full FDA approval for Alzheimer’s drug Leqembi
(Reuters) – Japanese drugmaker Eisai Co Ltd said on Saturday
Factbox-Who can get the newly approved Eisai and Biogen Alzheimer’s drug?
(Reuters) – The U.S. Food and Drug Administration on Friday
Roche shutters most trials of Alzheimer’s drug after failed trials
By Julie Steenhuysen CHICAGO (Reuters) – Swiss drugmaker Roche is
Eisai, Biogen Alzheimer’s drug could be available to some next year
By Deena Beasley and Julie Steenhuysen SAN FRANCISCO (Reuters) –
Rare success for Alzheimer’s research unlocks hope for future therapies
By Julie Steenhuysen CHICAGO (Reuters) -The first big breakthrough in
73-year-old man with Alzheimers reported missing in Newark
By Newark PD, Newark Public Safety Director Fritz G. Fragé
Analysis-Eisai’s trial success raises hope for Alzheimer’s prevention
By Julie Steenhuysen CHICAGO (Reuters) – Clear evidence this week
83-Year-Old Alzheimer’s Patient Reported Missing in Newark
NEWARK, NJ – Police in Newark have issued a silver
Biogen CEO to leave as Alzheimer’s drug struggles
(Reuters) – Biogen said on Tuesday its Chief Executive Michel
Alzheimer’s patient groups pressure U.S. to pay for Biogen drug
By Deena Beasley – Patient groups are mounting a public
REPORT: Biogen, Eisai Began Application For Alzheimer’s Drug
Biogen, and its Japanese partner Eisai, announced Monday that it